Boothbay Fund Management’s United Therapeutics UTHR Stock Holding History

Boothbay Fund Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-75,600	Closed	-$44.8M	–	2656
2026 Q1	$44.8M	Buy	+75,600	New	+$37.7M	0.58%	11
2025 Q4	–	Sell	-800	Closed	-$335K	–	2392
2025 Q3	$335K	Buy	+800	New	+$269K	﹤0.01%	1384
2022 Q2	–	Sell	-11,900	Closed	-$2.13M	–	2693
2022 Q1	$2.13M	Buy	+11,900	New	+$2.27M	0.05%	559
2021 Q2	–	Sell	-120	Closed	-$2.01M	–	2129
2021 Q1	$2.01M	Buy	120 +41	+52%	+$6.84K	0.08%	322
2020 Q4	$1.2M	Buy	+79	New	+$10.4K	0.04%	435

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Boothbay Fund Management's UTHR Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in United Therapeutics (UTHR) in Q2 2026: 782 shares worth $424K. The stake represents 0.01% of the portfolio and ranks #1599 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in UTHR as recently as Q3 2025.

Boothbay Fund Management first reported a position in UTHR in Q1 2017 and has held it in 9 quarters since. The position peaked at $1.58M in Q1 2021. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Boothbay Fund Management held 782 shares of United Therapeutics worth $424K as of Q2 2026.
United Therapeutics was a new Boothbay Fund Management position in Q2 2026.
United Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1599 holding.
Boothbay Fund Management first reported a position in United Therapeutics in Q1 2017 and has held it in 9 quarters since.
Boothbay Fund Management's United Therapeutics position peaked at $1.58M in Q1 2021.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.